Biotransformation Obese
Biotransformation Obese - Related Videos
01:16
Drug Biotransformation: Overview
0 Views •
2023
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28
Drug Biotransformation: Overview
0 Views •
2025
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
01:19
Factors Affecting Drug Biotransformation: Biological
0 Views •
2025
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity. Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects. Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:24
Obesity
0 Views •
2024
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
0 Views •
2025
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism. The drug's acidity or basicity is essential in determining the metabolic...
FAQs
Obesity can affect drug handling through changes in adipose tissue, broader physiology, and inflammation. These factors may alter metabolic capacity, as well as how a compound is distributed and cleared. Consequently, the same administered amount may produce different exposure or response in a patient with obesity, making physiological context important when interpreting pharmacokinetic findings.
Phase I reactions can modify a compound through oxidation, reduction, or hydrolysis, while phase II conjugation can further change its disposition. Considering these stages together helps clinicians evaluate whether metabolic processing may change compound activity, distribution, or clearance, rather than treating metabolism as a single uniform event.
Adipose tissue is relevant because obesity-related changes in it form part of the altered physiological setting in which compounds are processed and distributed. Its contribution should therefore be considered alongside inflammation and other physiological changes when researchers interpret metabolic capacity, drug exposure, and therapeutic response in patients with obesity.
An assessment should examine how obesity may affect exposure, distribution, clearance, and response, then relate those findings to the intended dose. This approach does not rely on a metabolic measurement alone; it integrates several disposition features to identify whether standard dosing may require more individualized consideration in clinical treatment.
Knowledge of altered biotransformation is most useful when selecting or evaluating therapy for a patient with obesity. Clinicians can use pharmacokinetic information to anticipate that metabolic capacity and clearance may not match assumptions derived from other populations. This interpretation supports safer dose selection and closer alignment between treatment and therapeutic response.
Researchers can use biotransformation findings to explain differences in therapeutic response among patients with obesity. If changes in metabolic processing affect compound activity, distribution, or clearance, measured exposure may not fully predict clinical behavior without considering those mechanisms. This context strengthens pharmacokinetic assessment and connects drug handling with individualized clinical treatment.